Detectability of low and intermediate or high risk prostate cancer with combined T2-weighted and diffusion-weighted MRI

European Radiology

Volumn 22, Issue 8, 2012, Pages 1812-1819

  Doo, Kyung Won ^b   Sung, Deuk Jae ^b   Park, Beom Jin ^b   Kim, Min Ju ^b   Cho, Sung Bum ^b   Oh, Yu Whan ^b   Ko, Young Hwii ^a   Yang, Kyung Sook ^b  

^a Korea University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Diffusion weighted magnetic resonance imaging; Gleason score; Magnetic resonance imaging; Prostate neoplasms; ROC curve

Indexed keywords

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER RISK; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; GLEASON SCORE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIODIAGNOSIS; SENSITIVITY AND SPECIFICITY; T2 WEIGHTED IMAGING;

AGED; AREA UNDER CURVE; DIFFUSION; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM GRADING; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84864660354     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-012-2430-5     Document Type: Article

References (31)

1. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT (2007) Imaging prostate cancer: a multidisciplinary perspective. Radiology 243:28-53
2. Pickles MD, Gibbs P, Sreenivas M, Turnbull LW(2006) Diffusionweighted imaging of normal and malignant prostate tissue at 3.0 T. J Magn Reson Imaging 23:130-134
3. Gibbs P, Pickles MD, Turnbull LW (2006) Diffusion imaging of the prostate at 3.0 Tesla. Invest Radiol 41:185-188
4. DeSouza NM, Reinsberg SA, Scurr ED, Brewster JM, Payne GS (2007) Magnetic resonance imaging in prostate cancer: the value of apparent diffusion coefficients for identifying malignant nodules. Br J Radiol 80:90-95
5. Kim CK, Park BK, Han JJ, Kang TW, Lee HM (2007) Diffusionweighted imaging of the prostate at 3 T for differentiation of malignant and benign tissue in transition and peripheral zones: preliminary results. J Comput Assist Tomogr 31:449-454
6. Haider MA, van der Kwast TH, Tanguay J et al (2007) Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol 189:323-328
7. Lim HK, Kim JK, Kim KA, Cho KS (2009) Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection-A multireader study. Radiology 250:145-151
8. Katahira K, Takahara T, Kwee TC et al (2011) Ultra-high-b-value diffusion-weighted MR imaging for the detection of prostate cancer: evaluation in 201 cases with histopathological correlation. Eur Radiol 21:188-196
9. Tan CH, Wang J, Kundra V (2011) Diffusion weighted imaging in prostate cancer. Eur Radiol 21:593-603
10. Vargas HA, Akin O, Franiel T et al (2011) Diffusion-weighted endorectal MR Imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology 259:775-784
11. Bostwick DG, Foster CS (1999) Predictive factors in prostate cancer: current concepts from the 1999 college of American pathologists conference on solid tumor prognostic factors and the 1999 World Health Organization second international consultation on prostate cancer. Semin Urol Oncol 17:222-272
12. Woodfield CA, Tung GA, Grand DJ, Pezzullo JA, Machan JT, Renzulli JF II (2010) Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. AJR Am J Roentgenol 194:W316-322
13. Tamada T, Sone T, Yoshimasa J et al (2008) Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissue and correlation with histologic grade. J Magn Reson Imaging 28:720-726
14. Itou Y, Nakanishi K, Narumi Y, Nishizawa Y, Tsukuma H (2011) Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: can ADC values contribute to assess the aggressiveness of prostate cancer? J Magn Reson Imaging 33:167-172
15. Turkbey B, Shah VP, Pang Y et al (2011) Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology 258:488-495
16. Yoshimitsu K, Kiyoshima K, Irie H et al (2008) Usefulness of apparent diffusion coefficient map in diagnosing prostate carcinoma: correlation with stepwise histopathology. J Magn Reson Imaging 27:132-139
17. Portalez D, Rollin G, Leandri P et al (2010) Prospective comparison of T2w-MRI and dynamic-contrast-enhanced MRI, 3D-MR spectroscopic imaging or diffusion-weighted MRI in repeat TRUSguided biopsies. Eur Radiol 20:2781-2790
18. Langer DL, van der Kwast TH, Evans AJ et al (2010) Prostate tissue composition and MR measurements: investigating the relationships between ADC, T2, K(trans), v(e), and corresponding histologic features. Radiology 255:485-494
19. Rosenkrantz AB, Mannelli L, Kong X et al (2011) Prostate cancer: utility of fusion of T2-weighted and high b-value diffusionweighted images for peripheral zone tumor detection and localization. J Magn Reson Imaging 34:95-100
20. Ahmed HU, Kirkham A, Arya M et al (2009) Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol 6:197-206
21. Kozlowski P, Chang SD, Jones EC, Berean KW, Chen H, Goldenberg SL (2006) Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis-correlation with biopsy and histopathology. J Magn Reson Imaging 24:108-113
22. Hricak H (2005) MR imaging and MR spectroscopic imaging in the pre-Treatment evaluation of prostate cancer. Br J Radiol 78: S103-S111
23. Girouin N, Mège-Lechevallier F, Tonina Senes A et al (2007) Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? Eur Radiol 17:1498-1509
24. Zakian KL, Sircar K, Hricak H et al (2005) Correlation of proton MR spectroscopic imaging with Gleason score based on stepsection pathologic analysis after radical prostatectomy. Radiology 234:804-814
25. Klotz L (2005) Active surveillance for prostate cancer: for whom? J Clin Oncol 23:8165-8169
26. Franiel T, Hamm B, Hricak H (2011) Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer. Eur Radiol 21:616-626
27. Oto A, Yang C, Kayhan A et al (2011) Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol 197:1382-1390
28. van As NJ, de Souza NM, Riches SF et al (2009) A study of diffusion-weighted magnetic resonance imaging in men with untreated localized prostate cancer on active surveillance. Eur Urol 56:981-987
29. Cohen MS, Hanley RS, Kurteva T et al (2008) Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey clinic medical center experience and an international meta-Analysis. Eur Urol 54:371-381
30. Corcoran NM, Hong MK, Casey RG et al (2011) Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU Int 108:E202-210
31. Bittencourt LK, Barentsz JO, de Miranda LC, Gasparetto EL (2012) Prostate MRI: diffusion-weighted imaging at 1.5 T correlates better with prostatectomy Gleason grades than TRUS-guided biopsies in peripheral zone tumours. Eur Radiol 22:468-475